We describe a 78-year-old man with right hemiballism as the presenting symptom of a metastatic occult adenocarcinoma of the lung. CT demonstrated two contrast-enhancing lesions: one in the left subthalamic region and the other in the left parietal region. Metastatic tumor was confirmed at autopsy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.34.2.204 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Retrospective, Single-Center Assessment of Changes in Pain, Agitation, and Delirium Management Before and During the COVID-19 Pandemic.
Crit Care Explor
January 2025
All authors: Department of Pharmacy, Brigham and Women's Hospital, Boston, MA.
Importance: Recent studies have found an association between COVID-19 infection and deeper sedation in mechanically ventilated patients, raising concerns about the impact of the COVID-19 pandemic on pain, agitation, and delirium (PAD) management practices overall.
Objectives: This study aimed to assess differences in PAD management in patients without COVID-19 infection in pre- and peri-COVID-19 pandemic timeframes.
Design, Setting, And Participants: This was a single-center, retrospective, pre-/post-cohort analysis of mechanically ventilated adult patients without COVID-19 infection admitted to an ICU in Boston, MA.
Effect of Triheptanoin on Caudate Atrophy and Motor Scores in Patients With Early-Stage Huntington Disease: A Phase II Study.
Neurology
January 2025
APHP- Salpêtrière Hospital, DMU BioGem, CNRS, INSERM, Paris Brain Institute, Sorbonne University.
Background And Objectives: Brain energy deficiency occurs at the early stage of Huntington disease (HD). Triheptanoin, a drug that targets the Krebs cycle, can restore a normal brain energetic profile in patients with HD. In this study, we aimed at assessing its efficacy on clinical and neuroimaging structural measures in HD.
View Article and Find Full Text PDFEffects and mechanisms of computerized cognitive training in Huntington's disease: protocol for a pilot study.
Neurodegener Dis Manag
January 2025
Turner Institute for Brain & Mental Health, School of Psychological Sciences, Faculty of Medicine, Nursing & Health Sciences, 18 Innovation Walk, Monash University, Clayton VIC 3800, Australia.
Huntington's disease (HD) causes progressive cognitive decline, with no available treatments. Computerized cognitive training (CCT) has shown efficacy in other populations, but its effects in HD are largely unknown. This pilot study will explore the effects and neural mechanisms of CCT in HD.
View Article and Find Full Text PDFDobutamine induced multifocal myoclonus in a patient with chronic kidney disease.
BMJ Case Rep
December 2024
Department of Cardiac Thoracic and Vascular Anesthesia, JSS Medical college and Hospital, Mysore, Karnataka, India.
Adverse drug reactions (ADRs) are common in clinical practice, especially among patients with multiple comorbidities and polypharmacy. The ADRs associated with medications may be minor or life-threatening. Many available ADR assessment scales and pharmacovigilance programmes have streamlined the early diagnosis and management of ADRs.
View Article and Find Full Text PDFEffect of Pretreatment with a Small Dose of Esketamine on Myoclonus Induced by Etomidate: A Randomized Controlled Trial.
Drug Des Devel Ther
December 2024
Department of Anesthesiology, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, People's Republic of China.
Background: Etomidate has been observed to precipitate myoclonus in patients undergoing induction of general anaesthesia. This study was designed to investigate the effect of pretreatment with a small dose of esketamine on the incidence of myoclonus induced by etomidate.
Methods: One hundred adult patients, who were scheduled to undergo selective operations with general anesthesia, were randomly divided into two groups, with one group receiving esketamine (Group E) and the other receiving normal saline (Group C).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!